TG Therapeutics Reports Strong Revenue, Shares Surge Despite Market Decline
TG Therapeutics shares surged 11.6% to $31.10 following the announcement of a preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million.
The strong financial performance, despite a broader market decline with the Nasdaq Composite falling over 200 points, showcases TG Therapeutics' competitiveness in the biopharmaceutical sector. The preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
This optimistic outlook is expected to boost shareholder confidence and attract more capital inflow, positioning TG Therapeutics favorably in a challenging market environment.
Trade with 70% Backtested Accuracy
Analyst Views on ADNT
About ADNT
About the author

- Goldman Sachs Reiterates Nvidia: Goldman Sachs maintains a Buy rating on Nvidia ahead of its earnings report, expecting investors to focus on visibility into 2027, non-traditional customer demand, and trends in the Chinese market, indicating strong market confidence in Nvidia's future growth.
- Benchmark Initiates Cava Rating: Benchmark initiates coverage of CAVA Group with a Buy rating and an $80 price target, reflecting its leadership position in the rapidly emerging Mediterranean dining market, which is expected to attract more investor interest in this burgeoning sector.
- BMO Capital Upgrades Brookfield: BMO upgrades Brookfield Asset Management from Market Perform to Outperform, citing attractive mid-teens distributable earnings growth prospects underpinned by continued fundraising momentum and fee rate resilience, showcasing the company's robust financial health.
- Bank of America Downgrades Qualcomm: Bank of America downgrades Qualcomm from Buy to Neutral, lowering the price target from $215 to $155 due to concerns over cyclical and structural weaknesses in the handset market, which may adversely affect its future performance.
- Revenue Growth: Adient plc reported $3.6 billion in revenue for Q1 2026, marking a 4% year-over-year increase primarily driven by favorable FX impacts from Europe and significant growth in China, effectively offsetting production challenges in North America and demonstrating the company's resilience in global markets.
- Adjusted EBITDA Performance: The adjusted EBITDA for the first quarter stood at $207 million, reflecting a 6% increase compared to the same period last year, with an EBITDA margin of 5.7%, indicating ongoing improvements in cost control and operational efficiency, which bolster confidence in future profitability.
- Shareholder Returns and Liquidity: The company repurchased $25 million in shares during the quarter, ending with a cash balance of $855 million and total liquidity of $1.7 billion, showcasing strong financial health and commitment to shareholders, which is expected to support future investments and growth.
- Outlook Enhancement: Adient raised its full-year 2026 sales guidance to approximately $14.6 billion, with adjusted EBITDA expectations of around $880 million and free cash flow of $125 million, reflecting the company's confidence in future growth, particularly through investments in automation and onshoring opportunities that will drive business performance.
- Earnings Beat: Adient's Q1 FY2026 non-GAAP EPS of $0.35 exceeded expectations by $0.16, indicating a significant improvement in the company's profitability.
- Revenue Growth: The company reported Q1 revenue of $3.64 billion, a 4.3% year-over-year increase that surpassed market expectations by $160 million, reflecting strong performance amid automotive industry recovery.
- Adjusted EBITDA Improvement: Q1 adjusted EBITDA reached $207 million, an $11 million year-over-year improvement, with adjusted EBITDA margins increasing from 5.6% to 5.7%, showcasing advancements in cost control and operational efficiency.
- Shareholder Returns and Upgraded Outlook: Adient repurchased approximately 1.2 million shares for $25 million in Q1 while raising FY26 revenue and free cash flow guidance to $14.6 billion and $125 million, respectively, reflecting optimism about future business performance.
- Financial Results Announcement: Adient announced its first quarter 2026 financial results, although specific figures were not disclosed, the company emphasized its leadership in the automotive seating sector, which is expected to positively impact future performance.
- Investor Conference Call: CEO Jerome Dorlack and CFO Mark Oswald will host a conference call at 8:30 AM Eastern to discuss the financial results, which is anticipated to attract investor interest and boost market confidence.
- Global Operational Scale: With over 65,000 employees across 29 countries and approximately 200 manufacturing and assembly plants, Adient demonstrates strong global production capacity and market coverage, aiding in meeting the demands of major OEMs.
- Forward-Looking Statement Risks: Adient highlighted several forward-looking statements in its report, emphasizing multiple risks related to the economy, market competition, and supply chains, cautioning investors to carefully assess the uncertainties surrounding future performance.
- Earnings Announcement: Adient (ADNT) is set to release its Q1 2023 earnings on February 4th before market open, with consensus EPS estimate at $0.19, reflecting a 29.6% year-over-year decline, and revenue estimate at $3.48 billion, down 0.3% year-over-year.
- Performance Expectations: Over the past two years, Adient has met EPS and revenue estimates 50% of the time, indicating a degree of volatility in financial performance that could impact investor confidence moving forward.
- Estimate Revisions: In the last three months, there have been no upward revisions to EPS estimates, with four downward adjustments, while revenue estimates also saw no upward revisions and three downward adjustments, reflecting a cautious market outlook on the company's future performance.
- Competitive Landscape: Despite Adient's joint venture and $1.2 billion wins in China showcasing its restructuring and automation efforts, market analysts suggest that cheaper alternatives may emerge by 2026, posing potential challenges to the company's growth trajectory.








